TGTX Earnings Date: Nov 2, 2026 (Estimated) — TG Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is TGTX's next earnings date?
TG Therapeutics, Inc. (TGTX) is expected to report Q3 2026 earnings on Monday, November 2, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.37 on revenue of $245.5M.
How did TGTX do in its last earnings report?
In its most recent report on Aug 3, 2026 (Q2 2026), TG Therapeutics, Inc. posted EPS of $0.05 versus the $0.43 estimate, a miss of 88.4%. Revenue was $240.3M against a $228.9M estimate. The stock's 1-day post-earnings move was -11.3%.
How much does TGTX stock move after earnings?
TGTX beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 11.8% (up or down) in the day after earnings.
About TG Therapeutics, Inc.
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-03 | Q2 2026 | 0.43 | 0.05 | -88.37% | $240.3M | ❌ Miss | -11.26% | -4.36% | +4.36% |
| 2026-05-06 | Q1 2026 | 0.27 | 0.18 | -33.33% | $204.9M | ❌ Miss | +16.26% | +17.84% | +12.35% |
| 2026-02-26 | Q4 2025 | 0.34 | 0.14 | -58.82% | $192.6M | ❌ Miss | +4.18% | -1.58% | +7.82% |
| 2025-11-03 | Q3 2025 | 0.22 | 2.43 | +1004.55% | $161.7M | ✅ Beat | -3.13% | -7.30% | -11.93% |
| 2025-03-03 | Q4 2024 | 0.08 | 0.15 | +87.50% | $108.2M | ✅ Beat | +14.39% | +27.75% | +31.04% |
| 2024-11-04 | Q3 2024 | 0.03 | 0.02 | -33.33% | $83.9M | ❌ Miss | -9.44% | +7.10% | +24.13% |
| 2024-08-06 | Q2 2024 | -0.05 | 0.04 | +180.00% | $73.5M | ✅ Beat | +19.58% | +19.99% | +28.30% |
| 2024-05-01 | Q1 2024 | -0.04 | -0.07 | -75.00% | $63.5M | ❌ Miss | +16.25% | +25.77% | +23.65% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $240.3M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 98.1% | $235.8M | +69.8% | $179.9M | $119.7M | $138.8M | $159.3M |
| License Revenue | 1.9% | $4.5M | +97.0% | $76K | $38K | $2.3M | $2.4M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.